Exagamglogene Autotemcel for Severe Sickle Cell Disease

Key Points

• Exagamglogene autotemcel is designed to reactivate fetal hemoglobin synthesis through targeted gene editing in patients with severe sickle cell disease.
• Ex vivo CRISPR-Cas9 gene editing targets the erythroid-specific enhancer region within autologous CD34+ hematopoietic stem and progenitor cells.
• Nonviral cell therapy approaches using exagamglogene autotemcel may enable durable genetic modification for managing severe sickle cell disease complications.